Table 2.
MedDRA System Organ Class Term MedDRA Preferred Term |
Intensity | GamTBvac n = 135 |
Placebo n = 45 |
||
---|---|---|---|---|---|
X (%) | Y | X (%) | Y | ||
Total number of volunteers with AEs | Mild | 53 (39.3%) | 89 | 14 (31.1%) | 31 |
Moderate | 5 (3.7%) | 9 | 1 (2.2%) | 1 | |
Blood and lymphatic system disorders Eosinophilia |
Mild | 2 (1.5%) | 3 | 1 (2.2%) | 1 |
Mild | 0 (0.0%) | 0 | 1 (2.2%) | 1 | |
Leukocytosis | Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
Neutrophilia | Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
Reticulocytosis | Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
Gastrointestinal disorders | Mild | 1 (0.7%) | 2 | 0 (0.0%) | 0 |
Nausea | Mild | 1 (0.7%) | 2 | 0 (0.0%) | 0 |
General disorders and administration site conditions | Mild | 3 (2.2%) | 3 | 0 (0.0%) | 0 |
Asthenia | Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
Hyperthermia | Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
Tissue infiltration Hepatobiliary disorders |
Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
Mild | 0 (0.0%) | 0 | 1 (2.2%) | 1 | |
Hyperbilirubinaemia | Mild | 0 (0.0%) | 0 | 1 (2.2%) | 1 |
Infections and infestations | Mild | 1 (0.7%) | 1 | 1 (2.2%) | 1 |
Moderate | 0 (0.0%) | 0 | 1 (2.2%) | 1 | |
Herpes virus infection | Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
Nasopharyngitis | Moderate | 0 (0.0%) | 0 | 1 (2.2%) | 1 |
Rhinitis | Mild | 0 (0.0%) | 0 | 1 (2.2%) | 1 |
Injury, poisoning, and procedural complications | Mild | 3 (2.2%) | 3 | 0 (0.0%) | 0 |
Vaccination complication | Mild | 3 (2.2%) | 3 | 0 (0.0%) | 0 |
Investigations | Mild | 41 (30.4%) | 66 | 13 (28.9%) | 27 |
Moderate | 4 (3.0%) | 8 | 0 (0.0%) | 0 | |
Alanine aminotransferase increased | Mild | 1 (0.7%) | 1 | 1 (2.2%) | 1 |
Aspartate aminotransferase increased | Moderate | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
Bilirubin conjugated increased | Mild | 2 (1.5%) | 2 | 1 (2.2%) | 1 |
Blood bilirubin increased | Mild | 8 (5.9%) | 10 | 5 (11.1%) | 6 |
C-reactive protein increased | Moderate | 3 (2.2%) | 4 | 0 (0.0%) | 0 |
Eosinophil count increased | Mild | 9 (6.7%) | 11 | 4 (8.9%) | 5 |
Eosinophil percentage increased | Moderate | 2 (1.5%) | 3 | 0 (0.0%) | 0 |
Hemoglobin decreased | Mild | 21 (15.6%) | 22 | 3 (6.7%) | 4 |
Lymphocyte count decreased | Mild | 3 (2.2%) | 3 | 3 (6.7%) | 3 |
Lymphocyte percentage decreased | Mild | 0 (0.0%) | 0 | 1 (2.2%) | 1 |
Monocyte count increased | Mild | 1 (0.7%) | 1 | 1 (2.2%) | 1 |
Neutrophil count decreased | Mild | 2 (1.5%) | 2 | 1 (2.2%) | 1 |
Neutrophil count increased | Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
pH urine increased | Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
Protein total increased | Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
White blood cell count decreased | Mild | 7 (5.2%) | 8 | 1 (2.2%) | 2 |
Metabolism and nutrition disorders | Mild | 2 (1.5%) | 2 | 0 (0.0%) | 0 |
Moderate | 1 (0.7%) | 1 | 0 (0.0%) | 0 | |
Hyperkalemia | Mild | 2 (1.5%) | 2 | 0 (0.0%) | 0 |
Moderate | 1 (0.7%) | 1 | 0 (0.0%) | 0 | |
Musculoskeletal and connective tissue disorders | Mild | 3 (2.2%) | 3 | 0 (0.0%) | 0 |
Myosclerosis | Mild | 3 (2.2%) | 3 | 0 (0.0%) | 0 |
Nervous system disorders | Mild | 3 (2.2%) | 3 | 0 (0.0%) | 0 |
Headache | Mild | 3 (2.2%) | 3 | 0 (0.0%) | 0 |
Respiratory, thoracic, and mediastinal disorders | Mild | 2 (1.5%) | 2 | 1 (2.2%) | 1 |
Cough | Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
Respiratory disorder | Mild | 1 (0.7%) | 1 | 1 (2.2%) | 1 |
Vascular disorders | Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |
Hypotension | Mild | 1 (0.7%) | 1 | 0 (0.0%) | 0 |